UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation

PloS one, 2013-02, Vol.8 (2), p.e57802-e57802

2013

Volltextzugriff (PDF)

ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure

Biomedicine & pharmacotherapy, 2024-06, Vol.175, p.116720, Article 116720

2024

Volltextzugriff (PDF)

Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice

International journal of pharmaceutics, 2020-05, Vol.581, p.119277, Article 119277

2020

Volltextzugriff (PDF)

Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c

Biomedicine & pharmacotherapy, 2023-10, Vol.166, p.115304-115304, Article 115304

2023

Volltextzugriff (PDF)

Human Keratinocytes Express Functional Toll-Like Receptor 3, 4, 5, and 9

Journal of investigative dermatology, 2007-02, Vol.127 (2), p.331-341

2007

Volltextzugriff (PDF)

Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs

Pharmacological research, 2023-04, Vol.190, p.106724-106724, Article 106724

2023

Volltextzugriff (PDF)

Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs

Biomedicine & pharmacotherapy, 2024-06, Vol.175, p.116644, Article 116644

2024

Volltextzugriff (PDF)

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice

International journal of pharmaceutics, 2019-02, Vol.556, p.172-180

2019

Volltextzugriff (PDF)

Natural deletion of mouse carboxylesterases Ces1c/d/e impacts drug metabolism and metabolic syndrome development

Biomedicine & pharmacotherapy, 2023-08, Vol.164, p.114956-114956, Article 114956

2023

Volltextzugriff (PDF)

Combined Methotrexate and Alitretinoin for the treatment of difficult‐to‐treat generalized prurigo nodularis: a case series

Journal of the European Academy of Dermatology and Venereology, 2021-08, Vol.35 (8), p.e516-e519

2021

Volltextzugriff (PDF)

Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis

PloS one, 2011-07, Vol.6 (7), p.e21772

2011

Volltextzugriff (PDF)

ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability

Pharmaceutics, 2021-10, Vol.13 (11), p.1761

2021

Volltextzugriff (PDF)

Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites

Frontiers in pharmacology, 2022-03, Vol.13, p.855000-855000

2022

Volltextzugriff (PDF)

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure

Pharmaceuticals (Basel, Switzerland), 2022-09, Vol.15 (9), p.1124

2022

Volltextzugriff (PDF)

P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)

Pharmaceuticals (Basel, Switzerland), 2021-10, Vol.14 (11), p.1087

2021

Volltextzugriff (PDF)

Ivermectine forte dose : nouveau traitement de la pédiculose pubienne avec localisation ciliaire ?

Annales de dermatologie et de vénéréologie, 2018-12, Vol.145 (12), p.S281-S282

2018

Volltextzugriff (PDF)

Intravenous immunoglobulins: an eye opener on the successful treatment of severe adult‐onset paraprotein‐associated xanthogranulomatosis

Clinical and experimental dermatology, 2021-10, Vol.46 (7), p.1346-1348

2021

Volltextzugriff (PDF)

Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism

Acta pharmaceutica Sinica. B, 2023-02, Vol.13 (2), p.618-631

2023

Volltextzugriff (PDF)

Xanthogranulomatoses sévères associées à une gammapathie monoclonale difficiles à traiter : intérêt des IgIV

Annales de dermatologie et de vénéréologie, 2020-12, Vol.147 (12), p.A330-A331

2020

Volltextzugriff (PDF)

Human organic anion transporting polypeptide (OATP) 1B3 and mouse OATP1A/1B affect liver accumulation of Ochratoxin A in mice

Toxicology and applied pharmacology, 2020-08, Vol.401, p.115072, Article 115072

2020

Volltextzugriff (PDF)

OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation

British journal of pharmacology, 2020-07, Vol.177 (13), p.3060-3074

2020

Volltextzugriff (PDF)

Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis

Biomedicines, 2022-01, Vol.10 (2), p.324

2022

Volltextzugriff (PDF)

The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib

Toxicology and applied pharmacology, 2024-04, Vol.485, p.116911-116911, Article 116911

2024

Volltextzugriff (PDF)

P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability

Pharmacological research, 2018-11, Vol.137, p.47-55

2018

Volltextzugriff (PDF)

P‐glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450‐3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib

International journal of cancer, 2018-10, Vol.143 (8), p.2029-2038

2018

Volltextzugriff (PDF)

1 – 25 von 445

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(271)
Mit Volltextzugriff
(368)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation

ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure

Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice

Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c

Human Keratinocytes Express Functional Toll-Like Receptor 3, 4, 5, and 9

Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs

Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice

Natural deletion of mouse carboxylesterases Ces1c/d/e impacts drug metabolism and metabolic syndrome development

Combined Methotrexate and Alitretinoin for the treatment of difficult‐to‐treat generalized prurigo nodularis: a case series

Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis

ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability

Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure

P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)

Ivermectine forte dose : nouveau traitement de la pédiculose pubienne avec localisation ciliaire ?

Intravenous immunoglobulins: an eye opener on the successful treatment of severe adult‐onset paraprotein‐associated xanthogranulomatosis

Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism

Xanthogranulomatoses sévères associées à une gammapathie monoclonale difficiles à traiter : intérêt des IgIV

Human organic anion transporting polypeptide (OATP) 1B3 and mouse OATP1A/1B affect liver accumulation of Ochratoxin A in mice

OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation

Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis

The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib

P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability

P‐glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450‐3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib

Suchergebnisse filtern